Pfizer’s $1.5B cuts; Biogen’s $1.15B buyout; AstraZeneca’s $80B ambition; RNA startup merger; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Whether you will be in San Diego for BIO, we hope you will join us for our pan­els on some of the most im­por­tant top­ics fac­ing the in­dus­try right now, from Chi­na ten­sions to fix­ing gene ther­a­py’s busi­ness mod­el to the stop-start mar­ket re­cov­ery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.